[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632458":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Adult patients with iTTP",null,"Patients with a confirmed diagnosis of iTTP, aged ≥ 18 years, treated with daratumumab for iTTP",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Juri A Giannotta, M.D.","CONTACT","+390255035273","juri.giannotta@policlinico.mi.it",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Angelo Bianchi Bonomi Hemophilia and Thrombosis Center","RECRUITING","Milan","Italy","IT",{"type":26,"coordinates":27},"Point",[28,29],12.59836,42.78235,{"lat":29,"lon":28},[32,33],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":14,"role":34,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100632458","daratumumab-in-immune-mediated-thrombotic-thrombocytopenic-purpura-100632458",false,"NCT07513948","Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura","DarTTP: an Observational, International, Multicentric Study on Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","DarTTP","Inclusion Criteria:\n\n* patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity \\\u003C10% with anti-ADAMTS13 antibodies detected);\n* aged ≥ 18 years;\n* male and female patients;\n* treated with daratumumab for iTTP.\n\nExclusion Criteria:\n\n* patients unwilling or unable to provide their informed consent;\n* follow-up \\\u003C 6 months after daratumumab administration.","ALL","18 Years","99 Years",{"count":49,"type":50},40,"ESTIMATED","OBSERVATIONAL","Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.",[54],"Thrombotic Thrombocytopenic Purpura, Acquired",[56,57,58],"daratumumab","thrombotic thrombocytopenic purpura","ADAMTS13","2026-04-13",{"date":61,"type":62},"2026-04-14","ACTUAL",{"date":64,"type":62},"2025-10-01",{"date":66,"type":50},"2026-08",{"name":5,"class":6},1]